The Bloomberg piece has another mistake that is significant, IMO: In reporting the 3Q10 sales of Enbrel, the article counts only the portion booked by PFE and overlooks the portion booked by AMGN.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”